Northern Trust
PRME icon

Northern Trust’s Prime Medicine PRME Stock Holding History

Northern Trust’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.09M Buy
886,716
+44,563
+5% +$170K ﹤0.01% 2726
2025
Q4 		$2.92M Buy
842,153
+234,164
+39% +$1.04M ﹤0.01% 2775
2025
Q3 		$3.37M Buy
607,989
+95,755
+19% +$389K ﹤0.01% 2728
2025
Q2 		$1.27M Sell
512,234
-15,075
-3% -$23.2K ﹤0.01% 3258
2025
Q1 		$1.05M Sell
527,309
-17,628
-3% -$45K ﹤0.01% 3251
2024
Q4 		$1.59M Buy
544,937
+20,389
+4% +$71.6K ﹤0.01% 3147
2024
Q3 		$2.03M Buy
524,548
+131,031
+33% +$607K ﹤0.01% 2994
2024
Q2 		$2.02M Buy
393,517
+53,519
+16% +$324K ﹤0.01% 2890
2024
Q1 		$2.38M Sell
339,998
-4,929
-1% -$37.4K ﹤0.01% 2868
2023
Q4 		$3.06M Buy
344,927
+11,969
+4% +$92.2K ﹤0.01% 2763
2023
Q3 		$3.18M Buy
332,958
+50,527
+18% +$656K ﹤0.01% 2687
2023
Q2 		$4.14M Buy
282,431
+192,352
+214% +$2.69M ﹤0.01% 2601
2023
Q1 		$1.11M Buy
90,079
+6,533
+8% +$106K ﹤0.01% 3188
2022
Q4 		$1.55M Buy
+83,546
New +$1.51M ﹤0.01% 3114

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Northern Trust's PRME Position: Q1 2026 in Review

Northern Trust increased its Prime Medicine (PRME) stake by 5.3% in Q1 2026, buying an estimated $170K and bringing the position to 886,716 shares worth $3.09M. The position accounts for ﹤0.01% of the portfolio, ranked #2726.

Northern Trust first reported a position in PRME in Q4 2022 and has held it in 14 quarters since. The position peaked at $4.14M in Q2 2023. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Northern Trust held 886,716 shares of Prime Medicine worth $3.09M as of Q1 2026.
  • Northern Trust bought 44,563 Prime Medicine shares in Q1 2026, an estimated $170K.
  • Prime Medicine made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #2726 holding.
  • Northern Trust first reported a position in Prime Medicine in Q4 2022 and has held it in 14 quarters since.
  • Northern Trust's Prime Medicine position peaked at $4.14M in Q2 2023.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.